	US 11,911,421 B2
	Probiotic composition including lactic acid bacterial strains and use thereof
Hsieh-Hsun Ho, Tainan (TW); Wen-Yang Lin, Tainan (TW); Yi-Wei Kuo, Tainan (TW); Yen-Yu Huang, Tainan (TW); and Jia-Hung Lin, Tainan (TW)
Assigned to GLAC BIOTECH CO., LTD., Tainan (TW)
Filed by GLAC BIOTECH CO., LTD., Tainan (TW)
Filed on Nov. 18, 2021, as Appl. No. 17/455,466.
Claims priority of application No. 110111649 (TW), filed on Mar. 30, 2021.
Prior Publication US 2022/0313752 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61P 3/10 (2006.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01)

CPC A61K 35/745 (2013.01) [A61K 35/747 (2013.01); A61P 3/10 (2018.01); C12N 1/205 (2021.05); C12R 2001/225 (2021.05)]

4 Claims

1. A method for alleviating type 1 diabetes mellitus (T1DM), comprising administering to a subject in need thereof a probiotic composition,

wherein the probiotic composition comprises Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9, which are deposited at the China Center for Type Culture Collection (CCTCC) respectively under accession numbers CCTCC M 2011127, CCTCC M 2011128, and CCTCC M 2014588,

wherein a number ratio of Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 ranges from 1:0.1:0.1 to 1:1:8, and

wherein the probiotic composition is in a dosage form for oral administration, and has a bacterial concentration of 10¹⁰CFU/mL, and

wherein the subject is administered with the probiotic composition twice daily for a 6-month treatment period.